Literature DB >> 15708696

Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.

Abhiram Prasad1, Gregg W Stone, Thomas D Stuckey, Costantino O Costantini, Peter J Zimetbaum, Michael McLaughlin, Roxana Mehran, Eulogio Garcia, James E Tcheng, David A Cox, Cindy L Grines, Alexandra J Lansky, Bernard J Gersh.   

Abstract

OBJECTIVES: We investigated the impact of diabetes mellitus on myocardial perfusion after primary percutaneous coronary intervention (PCI) utilizing myocardial blush grade (MBG) and ST-segment elevation resolution (STR).
BACKGROUND: Diabetes is an independent predictor of outcomes after primary PCI for acute myocardial infarction (AMI). Whether the poor prognosis is due to lower rates of myocardial reperfusion is unknown.
METHODS: Reperfusion success in those with and without diabetes mellitus was determined by measuring MBG (n = 1,301) and STR analysis (n = 700) in two substudies of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial among patients undergoing primary PCI for AMI.
RESULTS: There were no differences between those with or without diabetes with regard to postprocedural Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 (>95%), distribution of infarct-related artery, and the frequency of stent deployment or abciximab administration. Patients with diabetes mellitus were more likely to have absent myocardial perfusion (MBG 0/1, 56.0% vs. 47.1%, p = 0.01) and absent STR (20.3% vs. 8.1%, p = 0.002). Diabetes mellitus (hazard ratio [HR] 1.63 [95% confidence interval (CI) 1.17 to 2.28], p = 0.004) was an independent predictor of absent myocardial perfusion (MBG 0/1) and absent STR (HR 2.94 [95% CI 1.64 to 5.37], p = 0.005) by multivariate modeling.
CONCLUSIONS: Despite similar high rates of TIMI flow grade 3 after primary PCI in patients with and without diabetes, patients with diabetes are more likely to have abnormal myocardial perfusion as assessed by both incomplete STR and reduced MBG. Diminished microvascular perfusion in diabetics after primary PCI may contribute to adverse outcomes.

Entities:  

Mesh:

Year:  2005        PMID: 15708696     DOI: 10.1016/j.jacc.2004.10.054

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

Review 1.  Management of microvascular dysfunction and reperfusion injury.

Authors:  A Prasad; B J Gersh
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

2.  Vessel masking improves densitometric myocardial perfusion assessment.

Authors:  Tamás Ungi; Zsolt Zimmermann; Erika Balázs; András Lassó; Imre Ungi; Tamás Forster; András Palkó; Attila Nemes
Journal:  Int J Cardiovasc Imaging       Date:  2008-10-04       Impact factor: 2.357

Review 3.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

4.  Quantitative myocardial blush score (QuBE) allows the prediction of heart failure development in long-term follow-up in patients with ST-segment elevation myocardial infarction: Proof of concept study.

Authors:  Andrzej Tomasik; Tomasz Młyńczak; Edyta Nowak; Katarzyna Pigoń; Artur Iwasieczko; Mariusz Opara; Ewa Nowalany-Kozielska
Journal:  Cardiol J       Date:  2017-11-13       Impact factor: 2.737

5.  The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Alaa Quisi; Gökhan Alıcı
Journal:  J Clin Lab Anal       Date:  2018-06-26       Impact factor: 2.352

Review 6.  Diabetes-associated macrovascular complications: cell-based therapy a new tool?

Authors:  Maddalena Gili; Alberto Orsello; Sara Gallo; Maria Felice Brizzi
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

Review 7.  Diabetes and heart failure in the post-myocardial infarction patient.

Authors:  Jerry D Estep; David Aguilar
Journal:  Curr Heart Fail Rep       Date:  2006-12

8.  Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus--single center experience.

Authors:  Ri Bo Tang; Jian Zeng Dong; Xing Peng Liu; Dong Ping Fang; De Yong Long; Xiao Hui Liu; Rong Hui Yu; Fu Li Hu; Chun Shan Lu; Peng Hao; Jérôme Kalifa; Chang Sheng Ma
Journal:  J Interv Card Electrophysiol       Date:  2007-01-18       Impact factor: 1.900

Review 9.  Coronary microvascular dysfunction in the clinical setting: from mystery to reality.

Authors:  Joerg Herrmann; Juan Carlos Kaski; Amir Lerman
Journal:  Eur Heart J       Date:  2012-08-22       Impact factor: 29.983

10.  Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation.

Authors:  Giuseppe De Luca; C Michael Gibson; Francesco Bellandi; Sabina Murphy; Mauro Maioli; Marko Noc; Uwe Zeymer; Dariusz Dudek; Hans-Richard Arntz; Simona Zorman; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Tomasz Rakowski; Mariann Gyongyosi; Kurt Huber; Arnoud W J Van't Hof
Journal:  J Thromb Thrombolysis       Date:  2008-11-22       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.